HONG KONG – Cambridge, U.K.-based Astrazeneca plc has resumed phase I/II trials in Japan for AZD-1222, the experimental, adenovirus vector-based candidate coronavirus vaccine that it is co-developing with the University of Oxford. Read More
HONG KONG – Shanghai-headquartered Inventisbio Inc. brought in $147 million from a series D funding round to move its main products into phase II trials in the U.S. and China. Read More
In a valuable new deal for Cstone Pharmaceuticals Co. Ltd., Pfizer Inc. is taking a 9.9% stake in the company and licensing exclusive rights to commercialize its lead asset, the anti-PD-L1 antibody sugemalimab, in mainland China. Read More
PERTH, Australia – Regenerative medicine company Mesoblast Ltd. saw its stock drop 37% on the news that it received an FDA complete response letter to its BLA for Ryoncil (remestemcel-L) for the treatment of pediatric steroid-refractory acute graft-vs.-host disease. Read More
HONG KONG – Shanghai-based Bioshin Ltd., the Asia-Pacific arm of New Haven, Conn.-based Biohaven Pharmaceutical Holding Co. Ltd., has added $60 million to its war chest via a series A investment. Read More
HONG KONG – Xi’an, China-based Yufan Biotechnologies Co. Ltd. has partnered with Pittsburgh-based Abound Bio Inc. to discover and develop antibodies directing CAR T cells against cancer targets. Read More
With phase III vaccine trials nearly enrolled and data expected soon, a half-year of expedited development efforts, plus massive government funding may soon provide the ammunition needed to effectively stop the SARS-CoV-2 scourge of 2020. Read More
PERTH, Australia – Starpharma Holdings Ltd. completed a AU$45 million (US$32 million) placement to domestic and international investors that will see it advance its COVID-19 antiviral nasal spray. The treatment is based on the company’s antiviral dendrimer, SPL-7013. Read More
LONDON – Clinical care guidelines recommending the use of the HIV/AIDS combination lopinavir-ritonavir for the treatment of patients hospitalized with COVID-19 must now be updated, say the authors of a paper reporting the full results of a randomized U.K. study. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Allele, Axim, Bone, Casi, Chelation Partners, Cognate Bioservices, Eli Lilly, Evaxion, Fibrogenesis, Fosun, Juventas Cell Therapy, Koligo, Lakes, Lexaria Biosciences, Link Health, Luca Science, Luminarie Canada, Medicure, Moleculin Biotech, Navigo Proteins, Neurorx, Orgenesis, Pharco, Pluristem, Polyphor, R4D, Recce, Reliance Life Sciences, Relief, Repligen, Scancell, Serum Institute of India, Shenzhen Pregene, Sorrento, Taigen, University of Oxford, Vaxxas, Viralclear. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Astrazeneca, Corvus, Curevac, Eisai, Enlivex, FSD, Harbour Biomed, Johnson & Johnson, Kancera, Kyowa Kirin, Medincell, Mei, Moderna, Regeneron, Revelation, Revive, Shanghai Junshi, Zai Lab. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Baylx, Carsgen, I-Mab, Innovation, Kyowa Kirin, Medimetriks, Neuren, Organicell, Otsuka, Taigen, Windtree. Read More
